



The clinical practice of resuscitation science is dependent on discoveries generated in the basic science and animal 
laboratory and then translated into clinical trials for application in humans.  The successful implementation of prospective, 
randomized, controlled, clinical trials in the field of cardiac arrest remains challenging and continues to evolve.  Funding 
for clinical trials of cardiac arrest is limited, and there are significant obstacles to performing such studies because of the 
inability to obtain informed consent under these emergency circumstances. The absence of reliable national statistics on 
cardiac arrest, evaluation of neurological outcome, and potential confounders such as post-resuscitation hospital-based 
care and quality of cardiopulmonary resuscitation (CPR) continue to challenge cardiac arrest clinical trials.  Nonetheless, 
the immense public health burden of cardiac arrest is being recognized, appropriate public health initiatives to address the 
problem are being implemented, and the resuscitation research community is meeting this challenge.   
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Introduction
The national and international recom-
mendations that guide the treatment of 
cardiac arrest throughout the world are 
developed through a careful evidence 
evaluation process that formally asses-
ses the effectiveness of various resusci-
tation therapies reported in the literatu-
re.  The clinical practice of resuscitation 
science is dependent on discoveries 
generated in the basic science and ani-
mal laboratory and then translated into 
clinical trials for application in humans. 
The successful implementation of pro-
spective, randomized, controlled, cli-
nical trials in the field of cardiac arrest 
remains challenging and continues to 
evolve.  Recent data suggest that sur-
vival rates for cardiac arrest vary by 
nearly 500%, depending on location. 
(1)  This systematic bias could obscure 
the validity of a new intervention that 
could produce significant improvement 
in survival rates. Funding for clinical tri-
als of cardiac arrest is limited, and there 
are significant obstacles to performing 
such studies because of the inability to 
obtain informed consent under these 
emergency circumstances. The absen-
ce of reliable national statistics on car-
diac arrest, evaluation of neurological 
outcome, and potential confounders 
continue to challenge cardiac arrest cli-
nical trials.  Nonetheless, the immense 
public health burden of cardiac arrest 
is being recognized, appropriate public 
health initiatives to address the pro-
blem are being implemented, and the 
resuscitation research community is 
meeting this challenge.   
The Need for Clinical Trials
In a large North American study invol-
ving 10 geographic locations covering 
a catchment of 21.4 million people with 
20,520 cardiac arrests, the incidence 
of cardiac arrest was 50.1 per 100, 000 
population. (1)  Survival ranged from 
3.0% to 16.3% in these 10 centers with 
a median of 8.4%. (1)   This represents a 
huge health burden from cardiac arrest. 
In addition,  the number of years of 
life lost due to sudden cardiac arrest, 
appears to be at least 1,000,000 years 
annually in the United States. (2) At a 
very conservative valuation of $50 000 
per life-year, this places the cost of sud-
den cardiac death at about $50 trillion 
annually. On the basis of this number, 
the net present value of research that 
could produce a 10% reduction in mor-
tality from sudden cardiac arrest would 
be about $75 billion. (2)
Exception from Informed 
Consent
Despite the need for clinical trials to 
improve outcome from cardiac arrest, 
the inability to obtain informed consent 
from victims of cardiac arrest repre-
sents a challenge for resuscitation sci-
entists.  The goal of any cardiac arrest 
clinical trial is to evaluate a promising 
clinical intervention that holds potential 
for direct benefit to the patient, while 
doing everything possible to maintain 
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the welfare, safety, and rights of human 
subjects.  Each country implementing 
cardiac arrest clinical trials has appro-
ached this ethical dilemma differen-
tly.  In the United Stated, the Food and 
Drug Administration implemented its 
Final Rule (21 CFR 50.24) in Novem-
ber, 1996. (3)  This regulation makes 
cardiac arrest clinical research feasi-
ble, while, at the same time, manda-
ting an extensive process of Federal 
Wide Assurance, multiple Institutions 
Research Committee oversight and 
approval, community consultation and 
public notification prior to protocol ini-
tiation. One multi-center clinical resear-
ch consortium reported approval from 
58 Institutions Research Committees 
requiring about 6 months of time with 
an equal amount of time for comple-
tion of community consultation and 
public notification. (4)  While allowing 
clinical cardiac arrest research to be 
implemented, current regulations make 
this a time consuming, work-intensive, 
and ultimately very expensive process. 
Significant funding for such trials is now 
required, which can limit investigation 
to the few, most highly promising rese-
arch questions.  
Funding
Funding for cardiac arrest clinical trials 
is limited, and continues to impede rapid 
progress in the field.  One exception has 
been the development of the National 
Heart, Lung, and Blood Institute’s Resu-
scitation Outcomes Consortium in the 
United States. (5)  The Resuscitation 
Outcomes Consortium (ROC) was cre-
ated to conduct clinical research in the 
areas of cardiopulmonary resuscitation 
and traumatic injury. ROC consists of 
10 Regional Clinical Centers and a Data 
and Coordinating Center that provide 
the necessary infrastructure to conduct 
multiple collaborative clinical trials to aid 
rapid translation of promising scientific 
and clinical advances to improve resu-
scitation outcomes.  Recognizing the 
need to stimulate progress within the 
field, the National Institutes of Health 
will have invested approximately $120 
million over 12 years in this initiative by 
2016.  If the results of the ROC clini-
cal trials significantly improve outcome 
from cardiac arrest, continued funding 
for cardiac arrest clinical trials will be 
promising.  
Clinical Trial Issues
Cardiac arrest clinical trial study desi-
gns will be impacted by the true deno-
minator of the disease. Significant 
challenges remain in knowing the true 
statistics for incidence, epidemiolo-
gy, and surveillance of sudden cardiac 
arrest. The absence of a national man-
date for reporting all cardiac arrests 
and the resulting absence of reliable 
national statistics creates a challenge 
to the conduct of future clinical studies. 
(6)  This deficiency in understanding 
the epidemiology of cardiac arrest is a 
result of the lack of a consistent, stan-
dardized definition of sudden cardiac 
arrest and the use of surrogate data 
for epidemiological purposes, marked 
variation in the reported incidence of 
pediatric cardiac arrest, and limitations 
in the use of death certificates, such as 
misdiagnosis of underlying etiology, 
misreporting of diagnosis, and mis-
coding. As a result, comparisons of 
cardiac arrest outcomes have potenti-
al for significant bias.  Therefore, any 
study evaluating and reporting cardi-
ac arrest outcomes must account for 
these potential reporting biases and 
adhere to established or uniform end 
points such as those proposed under 
the Utstein guidelines. (7,8)
As resuscitation science has evol-
ved, interventions have become more 
successful in resuscitating, reviving, 
and discharging patients, and there is 
an increasing need to reconsider out-
comes such as length of survival, pre-
servation of neurologic function, and 
quality of survival.  Immediate resto-
ration of spontaneous and adequa-
te circulation is the highest priority of 
cardiac arrest resuscitation. However, 
progress in resuscitation science will 
not be measured by improved survival 
rate, but by neurologically intact sur-
vival rate.  Previous clinical trials have 
failed to provide significant neurologi-
cal protection to patients resuscitated 
from cardiac arrest. (9) This is changing 
rapidly with the advent of therapeutic 
hypothermia as a standard of post-
resuscitation care, which improves neu-
rological and functional outcome. (10) 
The Cerebral Performance Categories 
(CPCs), previously used as the primary 
outcome measure in cardiac arrest cli-
nical trials, is increasingly regarded as 
insufficient to adequately and sensitive-
ly assess cardiac arrest survivors . (11) 
Furthermore, discontinuing evaluation 
of cardiac arrest survivors at hospital 
discharge is increasingly regarded as 
an insufficient time period for follow up. 
More sensitive neurological and func-
tional assessments for cardiac arrest 
survivors that are feasible to implement 
in large, costly clinical trials need to be 
developed.  Standards for neurologi-
cal evaluation and appropriate time 
periods of assessment need to be defi-
ned and universally applied.  Improving 
neurological outcome for victims of 
cardiac arrest first requires measuring 
dysfunction.
Although randomized controlled cli-
nical cardiac arrest trials continue to 
have face validity and remain a “gold 
standard”, the significant potential for 
intrinsic (and sometimes subtle) con-
founders in cardiac arrest trials is an 
important issue to recognize.  Hospi-
tal-based post-resuscitation care (e.g. 
establishing Resuscitation Centers in 
the community) is one of the most signi-
ficant recent advances in treatment of 
cardiac arrest. One-year neurologically 
intact survival more than doubled (from 
26% to 56%) after implementing such 
an approach. (12)  The services provi-
ded by such centers vary by institution 
and often by patient.  Clinical trials mea-
suring cardiac arrest outcome without 
standardizing hospital-based care for 
all study patients are subject to signifi-
cant bias.  Variability in post-resuscita-
tion care remains a significant threat to 
clinical trial validity.  Similarly, the reco-
gnition of the importance of the quality 
of cardiopulmonary resuscitation (CPR) 
provided at the scene of cardiac arrest 
is a source of potential bias in clinical 
trials. (13-15) Like post-resuscitation 
care, quality of CPR varies by emergen-
cy medical services system, hospital, 
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and patient.  Non-blinded clinical trials 
risk differential quality of CPR in study 
groups. Without measurement, this 
potential bias will remain undetected. 
Electronic CPR monitoring with real-
time voice-prompted feedback, now 
widely available, represents a potential 
solution but is not universally appli-
ed.  Clinical cardiac arrest trials should 
electronically measure quality of CPR, 
compare, and report performance in all 
patient groups.  
Conclusion
The public health burden of cardiac 
arrest is enormous.  Combined with 
the development of new, promising 
clinical interventions, the need for high 
quality translational research in the field 
of cardiac arrest has never been grea-
ter.  Challenges to implementing clini-
cal cardiac arrest clinical trials include 
funding, inability to obtain informed 
consent, unreliable national statistics 
on cardiac arrest, selection of outcome 
variables, and potential confounders. 
Irrespective, public health initiatives to 
address cardiac arrest are being imple-
mented, and the resuscitation research 
community is meeting this challenge.   
